Precision cancer medicine最新文献_第8页

Cancer incidence and mortality in Shanghai: rates in 2016 and trends from 2002 to 2016 上海市癌症发病率和死亡率:2016年发病率及2002 - 2016年趋势

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-22-40

Chun‐xiao Wu, K. Gu, Yi Pang, P. Bao, Chunfang Wang, Liang Shi, Y. Gong, Yongmei Xiang, Jianming Dou, Mengyin Wu, Yan Shi, Chen Fu

引用次数: 0

How should clinicians manage metastatic non-small cell lung cancer patients with BRAF non-V600E mutations? 临床医生应该如何管理BRAF非V600E突变的转移性非小细胞肺癌癌症患者？

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-22-24

E. Urbanska

引用次数: 0

Introduction to Digital and Computational Pathology 数字和计算病理学导论

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.1007/978-3-030-84087-7_18

Bharat Jasani, R. Huss, C. Taylor

引用次数: 0

Precision cancer medicine in China: the Fudan University Shanghai Cancer Center experience 中国精准癌症医学：复旦大学上海癌症中心经验

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-26

Lei Dai, D. Ma, Zhihua Shao

引用次数: 0

Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib 使用液体活检治疗alk重排非小细胞肺癌患者的新一代测序:以氯拉替尼为重点

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-20-59

J. Blaquier, A. Cardona, A. Russo, C. Rolfo, G. Recondo

{"title":"Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib","authors":"J. Blaquier, A. Cardona, A. Russo, C. Rolfo, G. Recondo","doi":"10.21037/pcm-20-59","DOIUrl":"https://doi.org/10.21037/pcm-20-59","url":null,"abstract":": Next-generation sequencing (NGS) has introduced new applications in the molecular profiling of lung cancer, expanding its use from the essential molecular diagnosis in advanced stages, to disease monitoring and the study of resistance mechanisms to targeted therapies and, most recently, to immunotherapy. Cell-free DNA (cfDNA) NGS is an easily accessible form of liquid biopsy, with the potential of sequencing tumor DNA shed from different metastasis and capturing tumor heterogeneity and tumor clonal evolution during treatment. Lorlatinib, is a novel third-generation ALK inhibitor, and current standard treatment for patients that experience disease progression with crizotinib and a second-generation ALK inhibitor or in the front line setting. Preclinical studies on predictive biomarkers of response and resistance to lorlatinib have been conducted, shedding a light on potential biological mechanisms of primary and acquired resistance to this compound. With the emerging role of cfDNA NGS, molecular profiling opens new opportunities to try to unravel potential key biomarkers to predict lorlatinib efficacy and to further learn about the molecular processes that lead to lorlatinib resistance in the clinical practice. Herein, we discuss the current landscape of ALK targeted therapies, including clinical and preclinical data supporting the use of lorlatinib, and the current evidence of the role of liquid biopsies and its potential contribution in improving the care of patients with ALK-rearranged NSCLC treated with lorlatinib. 14","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43610550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The importance of standardized treatment planning and decision- making in radiation oncology for non-small-cell lung cancer— are current guidelines sufficiently strict for uniform target delineation?—a narrative literature review 标准化治疗计划和决策在非小细胞肺癌放射肿瘤学中的重要性——目前的指南是否足够严格以统一靶标划定?——叙事文学综述

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-22-17

Thomas Descamps, L. Moretti

引用次数: 0

Ineffective target therapy in non-small cell lung cancer harboring BRAF G466R mutation: a case report and biological rationale 携带BRAF G466R突变的非小细胞肺癌的无效靶向治疗:一个病例报告和生物学原理

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-24

F. Citarella, M. Russano, G. Perrone, G. Fazio, R. Giusti, B. Vincenzi, G. Tonini, D. Santini

引用次数: 1

Clinical implications of liquid biopsies in urogenital tumors: a narrative review 泌尿生殖道肿瘤液体活检的临床意义：叙述性综述

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-22-1

L. Chehade, A. H. Abdel Sater, H. Kourie, D. Mukherji, A. Shamseddine

{"title":"Clinical implications of liquid biopsies in urogenital tumors: a narrative review","authors":"L. Chehade, A. H. Abdel Sater, H. Kourie, D. Mukherji, A. Shamseddine","doi":"10.21037/pcm-22-1","DOIUrl":"https://doi.org/10.21037/pcm-22-1","url":null,"abstract":"Background and Objective: Liquid biopsy is a minimally invasive method for cancer management, with diagnostic, prognostic and predictive applications, which can overcome some of the limitations of tissue biopsy. The aim of this review is to present the available literature on the clinical implications of liquid biopsy use in urogenital tumors, specifically in prostate cancers (PCs) and bladder cancers (BCs). Methods: We searched PubMed and MEDLINE up to November 2, 2021 with no language restrictions. Key Content and Findings: The use of liquid biopsy in localized or metastatic hormone sensitive PC (mHSPC) is limited, given the low yield of detection. In contrast, the utility of liquid biopsy in metastatic castrate resistant PC (mCRPC) is more widely studied, with biomarkers such as circulating tumor cells (CTCs) and androgen receptor (AR) splice variant 7 (AR-V7) playing prognostic and predictive roles, and homologous recombination repair genes guiding therapy. Standardization of these assays and validation of their benefits in guiding clinical decisions are still needed. Liquid biopsy is approved for the diagnosis and monitoring of BC, but additional evidence is required on its therapeutic role, in patient selection for adjuvant and targeted therapy. Conclusions: Liquid biopsy technics have a promising role in guiding the diagnosis, prognosis and management of prostate and bladder tumors, as compared to traditional tissue biopsy. However, they still need to be standardized and validated in larger prospective trials.","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47000638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Primary lung secretory carcinoma: a case report 原发性肺分泌性癌1例

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-15

Huihua Li, D. Buehler, Jefree J. Schulte

引用次数: 1

A narrative review of the management of BRAF non-V600E mutated metastatic non-small cell lung cancer BRAF非V600E突变转移性癌症治疗的叙述性综述

Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-49

Inas Abuali, Chung-Shien Lee, N. Seetharamu

引用次数: 4